medicinova
announces
positive
clinical
results
regarding
ibudilast
prevention
peripheral
neuropathy
published
cancer
chemotherapy
pharmacology
la
jolla
globe
newswire
medicinova
biopharmaceutical
company
traded
nasdaq
global
market
nasdaq
mnov
jasdaq
market
tokyo
stock
exchange
code
number
today
announced
positive
clinical
findings
published
cancer
chemotherapy
pharmacology
regarding
ibudilast
treatment
prevention
peripheral
neuropathy
cipn
publication
entitled
ibudilast
prevention
acute
neurotoxicity
pilot
study
assessing
preliminary
efficacy
tolerability
pharmacokinetic
interactions
patients
metastatic
gastrointestinal
cancer
result
collaborative
effort
medicinova
janette
vardy
professor
cancer
medicine
university
sydney
concord
cancer
centre
australia
authors
report
ibudilast
oxaliplatin
resulted
improvement
stabilization
neurotoxicity
majority
participants
treated
oxaliplatin
prospective
sequential
crossover
study
conducted
assess
whether
ibudilast
reduce
acute
peripheral
neuropathy
symptoms
patients
metastatic
upper
gastrointestinal
colorectal
cancer
total
patients
consented
patients
completed
two
cycles
chemotherapy
one
cycle
conventional
chemotherapy
cycle
one
cycle
chemotherapy
concurrent
treatment
cycle
b
design
participant
acted
control
participants
underwent
number
assessments
neurotoxicity
day
cycle
completion
cycle
including
neurotoxicity
scale
osns
total
neuropathy
score
clinical
tnsc
functional
assessment
cancer
therapy
gynaecologic
oncology
fact
national
cancer
institute
common
terminology
criteria
adverse
events
neuropathy
subscale
major
findings
publication
follows
across
neurotoxicity
measures
majority
participants
experienced
either
improvement
worsening
neurotoxicity
ibudilast
treatment
according
osns
assessments
participants
reported
acute
neurotoxicity
grade
cycles
participants
unchanged
participants
improved
symptoms
grade
grade
ibudilast
according
score
changes
fact
tnsc
majority
participants
worsening
scores
day
end
cycle
cycle
b
compared
cycle
pharmacokinetic
analysis
indicated
effect
ibudilast
systemic
exposure
oxaliplatin
yuichi
iwaki
president
chief
executive
officer
medicinova
commented
pleased
report
positive
results
study
acute
neurotoxicity
predicts
chronic
cipn
usually
recurs
oxaliplatin
chemotherapy
cases
patients
experience
worsening
neurotoxicity
symptoms
continued
chemotherapy
makes
remarkable
half
participants
reported
improved
symptoms
acute
period
showed
improved
neurological
parameters
clinical
assessment
ibudilast
peripheral
neuropathy
peripheral
neuropathy
set
symptoms
caused
damage
nerves
outside
brain
spinal
cord
distant
nerves
called
peripheral
nerves
chemotherapy
drugs
used
treat
cancer
damage
peripheral
nerves
carry
sensations
hands
feet
damage
results
peripheral
neuropathy
cipn
common
side
effect
cancer
chemotherapy
commonly
people
complain
pins
needles
toes
fingers
cipn
may
affect
cancer
outcomes
due
reductions
chemotherapy
dosing
premature
treatment
discontinuation
profound
impact
quality
life
survivorship
according
included
patients
cipn
prevalence
measured
first
month
chemotherapy
months
months
seretny
et
neurotoxicity
important
issue
growing
number
cancer
survivors
highest
number
affected
patients
treated
breast
colon
cancer
ibudilast
ibudilast
orally
bioavailable
small
molecule
macrophage
migration
inhibitory
factor
mif
inhibitor
phosphodiesterase
pde
inhibitor
suppresses
cytokines
promotes
neurotrophic
factors
earlier
human
studies
demonstrated
significant
reductions
serum
mif
level
treatment
ibudilast
also
attenuates
activated
glial
cells
play
major
role
certain
neurological
conditions
ibudilast
neuroprotective
actions
demonstrated
preclinical
clinical
studies
provide
rationale
treatment
amyotrophic
lateral
sclerosis
als
progressive
multiple
sclerosis
ms
neurological
diseases
glioblastoma
gbm
substance
abuse
addiction
medicinova
developing
als
progressive
ms
neurological
conditions
degenerative
cervical
myelopathy
dcm
glioblastoma
substance
abuse
addiction
peripheral
neuropathy
well
prevention
acute
respiratory
distress
syndrome
ards
caused
medicinova
portfolio
patents
covers
use
ibudilast
treat
various
diseases
including
als
progressive
ms
drug
addiction
medicinova
medicinova
biopharmaceutical
company
founded
upon
developing
novel
therapeutics
treatment
diseases
unmet
medical
needs
primary
commercial
focus
market
medicinova
current
strategy
focus
vaccine
ibudilast
neurological
disorders
progressive
multiple
sclerosis
ms
amyotrophic
lateral
sclerosis
als
degenerative
cervical
myelopathy
dcm
substance
dependence
alcohol
use
disorder
methamphetamine
dependence
opioid
dependence
glioblastoma
gbm
well
prevention
acute
respiratory
distress
syndrome
ards
caused
tipelukast
fibrotic
diseases
nonalcoholic
steatohepatitis
nash
idiopathic
pulmonary
fibrosis
ipf
medicinova
pipeline
also
includes
bedoradrine
denibulin
information
medicinova
please
visit
statements
press
release
historical
nature
constitute
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
statements
include
without
limitation
statements
regarding
future
development
efficacy
statements
may
preceded
followed
otherwise
include
words
believes
expects
anticipates
intends
estimates
projects
could
may
would
considering
planning
similar
expressions
statements
involve
number
risks
uncertainties
may
cause
actual
results
events
differ
materially
expressed
implied
statements
factors
may
cause
actual
results
events
differ
materially
expressed
implied
statements
include
limited
risks
obtaining
future
partner
grant
funding
development
risks
raising
sufficient
capital
needed
fund
medicinova
operations
contribution
clinical
development
risks
uncertainties
inherent
clinical
trials
including
potential
cost
expected
timing
risks
associated
clinical
trials
designed
meet
fda
guidance
viability
development
considering
factors
product
development
commercialization
risks
uncertainty
whether
results
clinical
trials
predictive
results
later
stages
product
development
risk
delays
failure
obtain
maintain
regulatory
approval
risks
associated
reliance
third
parties
sponsor
fund
clinical
trials
risks
regarding
intellectual
property
rights
product
candidates
ability
defend
enforce
intellectual
property
rights
risk
failure
third
parties
upon
medicinova
relies
conduct
clinical
trials
manufacture
product
candidates
perform
expected
risk
increased
cost
delays
due
delays
commencement
enrollment
completion
analysis
clinical
trials
significant
issues
regarding
adequacy
clinical
trial
designs
execution
clinical
trials
timing
expected
filings
regulatory
authorities
medicinova
collaborations
third
parties
availability
funds
complete
product
development
plans
medicinova
ability
obtain
third
party
funding
programs
raise
sufficient
capital
needed
risks
uncertainties
described
medicinova
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
subsequent
periodic
reports
form
current
reports
form
undue
reliance
placed
statements
speak
date
hereof
medicinova
disclaims
intent
obligation
revise
update
statements
investor
contact
geoff
vice
president
medicinova
info
